Insmed Stock Forecast, Price & News

+0.06 (+0.24 %)
(As of 07/30/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume759,835 shs
Average Volume661,013 shs
Market Capitalization$2.55 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive INSM News and Ratings via Email

Sign-up to receive the latest news and ratings for Insmed and its competitors with MarketBeat's FREE daily newsletter.

Insmed logo

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.70 out of 5 stars

Medical Sector

884th out of 2,220 stocks

Pharmaceutical Preparations Industry

434th out of 869 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Insmed (NASDAQ:INSM) Frequently Asked Questions

Is Insmed a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Insmed stock.
View analyst ratings for Insmed
or view top-rated stocks.

What stocks does MarketBeat like better than Insmed?

Wall Street analysts have given Insmed a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Insmed wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Insmed's next earnings date?

Insmed is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Insmed

How can I listen to Insmed's earnings call?

Insmed will be holding an earnings conference call on Thursday, August 5th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 929-458-6194 with passcode "984249".

How were Insmed's earnings last quarter?

Insmed Incorporated (NASDAQ:INSM) released its quarterly earnings results on Thursday, May, 6th. The biopharmaceutical company reported ($0.89) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.91) by $0.02. The biopharmaceutical company had revenue of $40.21 million for the quarter, compared to analysts' expectations of $41.64 million. Insmed had a negative net margin of 190.36% and a negative trailing twelve-month return on equity of 103.03%. Insmed's quarterly revenue was up 9.1% on a year-over-year basis. During the same period last year, the firm earned ($0.74) earnings per share.
View Insmed's earnings history

How has Insmed's stock price been impacted by Coronavirus (COVID-19)?

Insmed's stock was trading at $21.25 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, INSM shares have increased by 15.8% and is now trading at $24.60.
View which stocks have been most impacted by COVID-19

What price target have analysts set for INSM?

6 brokerages have issued 12 month price targets for Insmed's shares. Their forecasts range from $44.00 to $60.00. On average, they anticipate Insmed's share price to reach $53.83 in the next twelve months. This suggests a possible upside of 118.8% from the stock's current price.
View analysts' price targets for Insmed
or view top-rated stocks among Wall Street analysts.

Who are Insmed's key executives?

Insmed's management team includes the following people:
  • Mr. William H. Lewis J.D., Pres, CEO & Chairman (Age 50)
  • Mr. Paolo Tombesi, Chief Financial Officer (Age 55)
  • Ms. Christine A. Pellizzari J.D., Chief Legal Officer & Corp. Sec. (Age 51)
  • Mr. Roger Adsett, Chief Commercial Officer (Age 50)
  • Dr. Paul D. Streck, Advisor (Age 55)

What is Will Lewis' approval rating as Insmed's CEO?

14 employees have rated Insmed CEO Will Lewis on Will Lewis has an approval rating of 78% among Insmed's employees.

Who are some of Insmed's key competitors?

What other stocks do shareholders of Insmed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insmed investors own include Gilead Sciences (gild), AbbVie (ABBV), Johnson & Johnson (JNJ), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA) and Geron (GERN).

What is Insmed's stock symbol?

Insmed trades on the NASDAQ under the ticker symbol "INSM."

Who are Insmed's major shareholders?

Insmed's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Alliancebernstein L.P. (1.98%), Scout Investments Inc. (0.33%), Rice Hall James & Associates LLC (0.29%), Oak Ridge Investments LLC (0.08%) and Harbor Investment Advisory LLC (0.00%). Company insiders that own Insmed stock include Alfred Altomari, Christine A Pellizzari, John Goll, John Soriano, Melvin Md Sharoky, Orlov S Nicole Schaeffer and William Lewis.
View institutional ownership trends for Insmed

Which major investors are selling Insmed stock?

INSM stock was sold by a variety of institutional investors in the last quarter, including Rice Hall James & Associates LLC, and Oak Ridge Investments LLC. Company insiders that have sold Insmed company stock in the last year include Alfred Altomari, Christine A Pellizzari, John Soriano, Melvin Md Sharoky, Orlov S Nicole Schaeffer, and William Lewis.
View insider buying and selling activity for Insmed
or view top insider-selling stocks.

Which major investors are buying Insmed stock?

INSM stock was purchased by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Scout Investments Inc., and Harbor Investment Advisory LLC.
View insider buying and selling activity for Insmed
or or view top insider-buying stocks.

How do I buy shares of Insmed?

Shares of INSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Insmed's stock price today?

One share of INSM stock can currently be purchased for approximately $24.60.

How much money does Insmed make?

Insmed has a market capitalization of $2.55 billion and generates $164.41 million in revenue each year. The biopharmaceutical company earns $-294,090,000.00 in net income (profit) each year or ($3.01) on an earnings per share basis.

How many employees does Insmed have?

Insmed employs 373 workers across the globe.

What is Insmed's official website?

The official website for Insmed is

Where are Insmed's headquarters?

Insmed is headquartered at 700 US Highway 202/206, Bridgewater NJ, 08807.

How can I contact Insmed?

Insmed's mailing address is 700 US Highway 202/206, Bridgewater NJ, 08807. The biopharmaceutical company can be reached via phone at 908-977-9900 or via email at [email protected]

This page was last updated on 8/1/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.